Human Molecular Genetics Advance Access published online on February 5, 2004
Human Molecular Genetics, doi:10.1093/hmg/ddh069
© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital Du Cane Road, London W12 0NN, UK
* To whom correspondence should be addressed. E-mail: carol.shoulders{at}csc.mrc.ac.uk.
Coronary heart disease is the leading cause of death in developed countries. This alarming statistic is partly attributable to lifestyle, and partly due to the genetic factors that make humans highly susceptible to atherosclerotic vascular disease. The principal metabolic causes of atherosclerosis include hyperlipidemia, hypertension, obesity, insulin resistance and diabetes mellitus. Here we discuss the aetiology of familial combined hyperlipidemia (FCHL), a highly atherogenic disorder affecting 1-2% of the Western world. Genome-wide linkage studies indicate that more than three genes contribute to the pernicious lipid profile of FCHL, and that these genes reside within the 1q21-23, 11p14.1-q12.1 and 16q22-24.1 chromosomal regions. Other loci include 1p31, 6q16.1-16.3 and 8p23.3-22, but the linkage data for these are not yet persuasive. Combined linkage and association analyses provide compelling evidence for the involvement of two distinct alleles at the APOA1/C3/A4/A5 gene cluster in the transmission of FCHL. An important lesson arising from the study of a complex genetic disorder, such as FCHL, that lacks a consensus on diagnostic criteria, is that an understanding of complex genetic disorders can derive from comparative analyses of genome-wide linkage data generated from conditions that share phenotypic overlap. The identification of potential genetic overlap between FCHL and the Metabolic Syndrome, which is estimated to affect 47 million Americans, promises to deliver new targets for reducing the risk of important conditions such as cardiovascular disease and stroke.
Article
Genetics of Familial Combined Hyperlipidemia and Risk of Coronary Heart Disease
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G Ferns, V Keti, and B Griffin Investigation and management of hypertriglyceridaemia J. Clin. Pathol., November 1, 2008; 61(11): 1174 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Grallert, E.-M. Sedlmeier, C. Huth, M. Kolz, I. M. Heid, C. Meisinger, C. Herder, K. Strassburger, A. Gehringer, M. Haak, et al. APOA5 variants and metabolic syndrome in Caucasians J. Lipid Res., December 1, 2007; 48(12): 2614 - 2621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Naoumova, H. Kindler, L. Leccisotti, M. Mongillo, M. T. Khan, C. Neuwirth, M. Seed, P. Holvoet, J. Betteridge, and P. G. Camici Pioglitazone Improves Myocardial Blood Flow and Glucose Utilization in Nondiabetic Patients With Combined Hyperlipidemia: A Randomized, Double-Blind, Placebo-Controlled Study J. Am. Coll. Cardiol., November 5, 2007; (2007) j.jacc.2007.07.070v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Plata, C. R. Sussman, A. Sindic, J. O. Liang, D. B. Mount, Z. M. Josephs, M.-H. Chang, and M. F. Romero Zebrafish Slc5a12 Encodes an Electroneutral Sodium Monocarboxylate Transporter (SMCTn): A COMPARISON WITH THE ELECTROGENIC SMCT (SMCTe/Slc5a8) J. Biol. Chem., April 20, 2007; 282(16): 11996 - 12009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C.G.J. Brouwers, N. Kono, M. M.J. van Greevenbroek, C. J.H. van der Kallen, A. J. Lusis, T. W.A. de Bruin, and R. M. Cantor Longitudinal Differences in Familial Combined Hyperlipidemia Quantitative Trait Loci. Arterioscler Thromb Vasc Biol, June 1, 2006; 26(6): e118 - e119. [Full Text] [PDF]
|
|